Deucravacitinib在银屑病关节炎筛查阳性的斑块型银屑病患者中的应用：关节疼痛的改善和肌肉骨骼症状的影响

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-08-01 Epub Date: 2025-05-30 DOI:10.1007/s13555-025-01428-9

Joseph F Merola, Philip J Mease, April W Armstrong, Vibeke Strand, Thomas Lehman, Stefan Varga, Jiyoon C Choi, Brandon Becker, Yichen Zhong, Matthew J Colombo, Diamant Thaçi, Androniki Bili, Alice B Gottlieb

{"title":"Deucravacitinib在银屑病关节炎筛查阳性的斑块型银屑病患者中的应用：关节疼痛的改善和肌肉骨骼症状的影响","authors":"Joseph F Merola, Philip J Mease, April W Armstrong, Vibeke Strand, Thomas Lehman, Stefan Varga, Jiyoon C Choi, Brandon Becker, Yichen Zhong, Matthew J Colombo, Diamant Thaçi, Androniki Bili, Alice B Gottlieb","doi":"10.1007/s13555-025-01428-9","DOIUrl":null,"url":null,"abstract":"Introduction: For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs. placebo or apremilast on joint pain and the impact of musculoskeletal symptoms at weeks 16 and 24 in patients from the POETYK psoriasis (PSO-1; NCT03624127) and POETYK PSO second (PSO-2; NCT03611751) trials who self-reported joint symptoms.Methods: During screening in each trial, patients with psoriasis who reported musculoskeletal complaints completed the self-administered Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. Scores of ≥ 47 constituted positive screens (PASE positive). Joint pain and the impact of musculoskeletal symptoms were measured using a visual analog scale (VAS), with higher scores denoting worse disease burden.Results: This pooled analysis included 185 patients who screened as PASE-positive in the combined POETYK PSO-1 and PSO-2 trials. Improvement from baseline was greater in patients treated with deucravacitinib vs. placebo at week 16 for joint pain VAS (- 15.2 vs. - 3.2) and joint disease VAS (- 17.4 vs. - 3.8). Improvements from baseline were also greater for patients treated with deucravacitinib vs. apremilast for joint pain VAS (- 22.8 vs. - 8.6) and joint disease VAS (- 19.6 vs. - 8.8) scores at week 24. Greater proportions of deucravacitinib-treated patients also achieved 30%, 50%, and 70% improvements in joint pain and musculoskeletal symptoms and impact VAS scores at weeks 16 and 24 than those who received placebo or apremilast.Conclusion: Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2281-2293"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256370/pdf/","citationCount":"0","resultStr":"{\"title\":\"Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.\",\"authors\":\"Joseph F Merola, Philip J Mease, April W Armstrong, Vibeke Strand, Thomas Lehman, Stefan Varga, Jiyoon C Choi, Brandon Becker, Yichen Zhong, Matthew J Colombo, Diamant Thaçi, Androniki Bili, Alice B Gottlieb\",\"doi\":\"10.1007/s13555-025-01428-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs. placebo or apremilast on joint pain and the impact of musculoskeletal symptoms at weeks 16 and 24 in patients from the POETYK psoriasis (PSO-1; NCT03624127) and POETYK PSO second (PSO-2; NCT03611751) trials who self-reported joint symptoms.Methods: During screening in each trial, patients with psoriasis who reported musculoskeletal complaints completed the self-administered Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. Scores of ≥ 47 constituted positive screens (PASE positive). Joint pain and the impact of musculoskeletal symptoms were measured using a visual analog scale (VAS), with higher scores denoting worse disease burden.Results: This pooled analysis included 185 patients who screened as PASE-positive in the combined POETYK PSO-1 and PSO-2 trials. Improvement from baseline was greater in patients treated with deucravacitinib vs. placebo at week 16 for joint pain VAS (- 15.2 vs. - 3.2) and joint disease VAS (- 17.4 vs. - 3.8). Improvements from baseline were also greater for patients treated with deucravacitinib vs. apremilast for joint pain VAS (- 22.8 vs. - 8.6) and joint disease VAS (- 19.6 vs. - 8.8) scores at week 24. Greater proportions of deucravacitinib-treated patients also achieved 30%, 50%, and 70% improvements in joint pain and musculoskeletal symptoms and impact VAS scores at weeks 16 and 24 than those who received placebo or apremilast.Conclusion: Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"2281-2293\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256370/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01428-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01428-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：银屑病患者，银屑病关节炎可以是一个痛苦的合并症，往往是未确诊。因此，有必要进行更多的研究，以了解哪种治疗银屑病可以同时缓解皮肤和关节症状。本分析旨在比较deucravacitinib与安慰剂或阿普雷米司特对POETYK型银屑病(PSO-1；NCT03624127)和POETYK第二PSO (PSO-2；NCT03611751)自我报告关节症状的试验。方法：在每个试验的筛查过程中，报告肌肉骨骼疾病的银屑病患者完成自我管理的银屑病关节炎筛查和评估（PASE）问卷。≥47分为阳性筛查（PASE阳性）。使用视觉模拟量表（VAS）测量关节疼痛和肌肉骨骼症状的影响，得分越高表示疾病负担越重。结果：这项汇总分析包括185名在POETYK PSO-1和PSO-2联合试验中筛选为pase阳性的患者。在第16周，接受deucravacitinib治疗的患者在关节疼痛VAS （- 15.2 vs - 3.2）和关节疾病VAS （- 17.4 vs - 3.8）方面较基线的改善更大。在第24周，deucravacitinib和apremilast治疗的患者在关节疼痛VAS评分（- 22.8比- 8.6）和关节疾病VAS评分（- 19.6比- 8.8）方面的改善也比基线更大。在第16周和第24周，deucravacitinib治疗的患者在关节疼痛和肌肉骨骼症状以及影响VAS评分方面也比接受安慰剂或阿普雷米司特治疗的患者改善了30%、50%和70%。结论：本汇总分析的结果表明，deucravacitinib可用于银屑病患者有效治疗皮肤和关节症状。本文提供图形摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.

Introduction: For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs. placebo or apremilast on joint pain and the impact of musculoskeletal symptoms at weeks 16 and 24 in patients from the POETYK psoriasis (PSO-1; NCT03624127) and POETYK PSO second (PSO-2; NCT03611751) trials who self-reported joint symptoms.

Methods: During screening in each trial, patients with psoriasis who reported musculoskeletal complaints completed the self-administered Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire. Scores of ≥ 47 constituted positive screens (PASE positive). Joint pain and the impact of musculoskeletal symptoms were measured using a visual analog scale (VAS), with higher scores denoting worse disease burden.

Results: This pooled analysis included 185 patients who screened as PASE-positive in the combined POETYK PSO-1 and PSO-2 trials. Improvement from baseline was greater in patients treated with deucravacitinib vs. placebo at week 16 for joint pain VAS (- 15.2 vs. - 3.2) and joint disease VAS (- 17.4 vs. - 3.8). Improvements from baseline were also greater for patients treated with deucravacitinib vs. apremilast for joint pain VAS (- 22.8 vs. - 8.6) and joint disease VAS (- 19.6 vs. - 8.8) scores at week 24. Greater proportions of deucravacitinib-treated patients also achieved 30%, 50%, and 70% improvements in joint pain and musculoskeletal symptoms and impact VAS scores at weeks 16 and 24 than those who received placebo or apremilast.

Conclusion: Findings from this pooled analysis suggest that deucravacitinib may be used in patients with psoriasis to effectively treat both dermatologic and joint symptoms. Graphical abstract available for this article.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.